{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T15:03:08Z","timestamp":1793286188293,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100015862","name":"Chinese Nutrition Society","doi-asserted-by":"publisher","award":["CNS-BMSG2021-07"],"award-info":[{"award-number":["CNS-BMSG2021-07"]}],"id":[{"id":"10.13039\/100015862","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015862","name":"Chinese Nutrition Society","doi-asserted-by":"publisher","award":["CNS-DSM2018A30"],"award-info":[{"award-number":["CNS-DSM2018A30"]}],"id":[{"id":"10.13039\/100015862","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073538"],"award-info":[{"award-number":["82073538"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011324","name":"Qingdao University","doi-asserted-by":"publisher","award":["QYFYWZLL25549"],"award-info":[{"award-number":["QYFYWZLL25549"]}],"id":[{"id":"10.13039\/501100011324","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Nutritional Biochemistry"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jnutbio.2025.110136","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T01:07:48Z","timestamp":1759540068000},"page":"110136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["n - 3 polyunsaturated fatty acids mediate hyodeoxycholic acid-FXR signaling to ameliorate metabolic dysfunction-associated fatty liver disease"],"prefix":"10.1016","volume":"147","author":[{"given":"Yuan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-fang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-xuan","family":"Cong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin-peng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-ping","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-cen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong-cheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J","family":"Sinclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5227-5565","authenticated-orcid":false,"given":"Duo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-fei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jnutbio.2025.110136_bib0001","first-page":"388","article-title":"Global multi-stakeholder endorsement of the MAFLD definition[J]","volume":"7","author":"M\u00e9ndez-S\u00e1nchez","year":"2022","journal-title":"Lancet Gastroenterol"},{"issue":"9","key":"10.1016\/j.jnutbio.2025.110136_bib0002","first-page":"851","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis[J]","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol"},{"issue":"14","key":"10.1016\/j.jnutbio.2025.110136_bib0003","first-page":"1521","article-title":"Nonalcoholic fatty liver disease: a systematic review (vol 313, pg 2263, 2015)[J]","volume":"314","author":"Rinella","year":"2015","journal-title":"Jama-J Am Med Assoc"},{"issue":"10","key":"10.1016\/j.jnutbio.2025.110136_bib0004","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease[J]","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.jnutbio.2025.110136_bib0005","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1007\/s00394-021-02772-0","article-title":"The effects of fish oil plus vitamin D3 intervention on non-alcoholic fatty liver disease: a randomized controlled trial[J]","volume":"61","author":"Guo","year":"2022","journal-title":"Eur J Nutr"},{"key":"10.1016\/j.jnutbio.2025.110136_bib0006","article-title":"Concentrated fish oil ameliorates non-alcoholic fatty liver disease by regulating fibroblast growth factor 21-adiponectin axis[J]","volume":"100","author":"Guo","year":"2022","journal-title":"Nutrition"},{"issue":"4","key":"10.1016\/j.jnutbio.2025.110136_bib0007","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.jhep.2011.08.018","article-title":"Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis[J]","volume":"56","author":"Parker","year":"2012","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jnutbio.2025.110136_bib0008","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.clnu.2017.01.003","article-title":"Fatty acid and non-alcoholic fatty liver disease: meta-analyses of case-control and randomized controlled trials[J]","volume":"37","author":"Guo","year":"2018","journal-title":"Clin Nutr"},{"issue":"1","key":"10.1016\/j.jnutbio.2025.110136_bib0009","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cmet.2016.05.005","article-title":"B\u00e4ckhed F. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism[J]","volume":"24","author":"Wahlstr\u00f6m","year":"2016","journal-title":"Cell Metab"},{"issue":"2","key":"10.1016\/j.jnutbio.2025.110136_bib0010","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nrgastro.2017.119","article-title":"Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis[J]","volume":"15","author":"Jia","year":"2018","journal-title":"Nat Rev Gastro Hepat"},{"issue":"8","key":"10.1016\/j.jnutbio.2025.110136_bib0011","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nrd2619","article-title":"Targeting bile-acid signalling for metabolic diseases[J]","volume":"7","author":"Thomas","year":"2008","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"10.1016\/j.jnutbio.2025.110136_bib0012","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1038\/s41591-018-0222-4","article-title":"Gut microbiota and intestinal FXR mediate the clinical benefits of metformin[J]","volume":"24","author":"Sun","year":"2018","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.jnutbio.2025.110136_bib0013","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41564-023-01570-0","article-title":"Gut commensal Christensenella minuta modulates host metabolism via acylated secondary bile acids[J]","volume":"9","author":"Liu","year":"2024","journal-title":"Nat Microbiol"},{"issue":"5","key":"10.1016\/j.jnutbio.2025.110136_bib0014","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41575-020-00404-2","article-title":"The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer[J]","volume":"18","author":"Sun","year":"2021","journal-title":"Nat Rev Gastro Hepat"},{"issue":"10","key":"10.1016\/j.jnutbio.2025.110136_bib0015","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/j.cmet.2023.07.011","article-title":"Hyodeoxycholic acid alleviates non-alcoholic fatty liver disease through modulating the gut-liver axis[J]","volume":"35","author":"Kuang","year":"2023","journal-title":"Cell Metab"},{"issue":"5","key":"10.1016\/j.jnutbio.2025.110136_bib0016","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1039\/D3FO02319B","article-title":"Effects of dietary supplementation of fish oil plus vitamin D3 on gut microbiota and fecal metabolites, and their correlation with nonalcoholic fatty liver disease risk factors: a randomized controlled trial[J]","volume":"15","author":"Li","year":"2024","journal-title":"Food Funct"},{"key":"10.1016\/j.jnutbio.2025.110136_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.jnutbio.2023.109484","article-title":"n - 3 polyunsaturated fatty acids in phospholipid or triacylglycerol form attenuate nonalcoholic fatty liver disease via mediating cannabinoid receptor 1\/adiponectin\/ceramide pathway[J]","volume":"123","author":"Chen","year":"2024","journal-title":"J Nutr Biochem"},{"issue":"1","key":"10.1016\/j.jnutbio.2025.110136_bib0018","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1172\/JCI76738","article-title":"Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease[J]","volume":"125","author":"Jiang","year":"2015","journal-title":"J Clin Investig"},{"issue":"1","key":"10.1016\/j.jnutbio.2025.110136_bib0019","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/s41467-021-21744-w","article-title":"Hyocholic acid species as novel biomarkers for metabolic disorders[J]","volume":"12","author":"Zheng","year":"2021","journal-title":"Nat Comms"},{"issue":"13","key":"10.1016\/j.jnutbio.2025.110136_bib0020","doi-asserted-by":"crossref","first-page":"7251","DOI":"10.1039\/D2FO00081D","article-title":"Coffee peel extracts ameliorate non-alcoholic fatty liver disease a fibroblast growth factor 21-adiponectin signaling pathway[J]","volume":"13","author":"Fan","year":"2022","journal-title":"Food Funct"},{"key":"10.1016\/j.jnutbio.2025.110136_bib0021","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.mam.2018.03.001","article-title":"Omega-3 fatty acids and non-alcoholic fatty liver disease: evidence of efficacy and mechanism of action[J]","volume":"64","author":"Scorletti","year":"2018","journal-title":"Mol Aspects Med"},{"issue":"4","key":"10.1016\/j.jnutbio.2025.110136_bib0022","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.cmet.2020.11.017","article-title":"Hyocholic acid species improve glucose homeostasis through a distinct TGR5 and FXR signaling mechanism[J]","volume":"33","author":"Zheng","year":"2021","journal-title":"Cell Metab"},{"issue":"10","key":"10.1016\/j.jnutbio.2025.110136_bib0023","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.bbalip.2019.05.016","article-title":"Turnover of bile acids in liver, serum and caecal content by high-fat diet feeding affects hepatic steatosis in rats[J]","volume":"1864","author":"Tang","year":"2019","journal-title":"Biochimica et Biophysica Acta (BBA) - Mol Cell Biol Lipids"},{"issue":"5","key":"10.1016\/j.jnutbio.2025.110136_bib0024","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s13238-020-00804-9","article-title":"Targeting the alternative bile acid synthetic pathway for metabolic diseases[J]","volume":"12","author":"Jia","year":"2021","journal-title":"Protein Cell"},{"issue":"10","key":"10.1016\/j.jnutbio.2025.110136_bib0025","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.3390\/cells10102656","article-title":"Oxysterol 7-\u03b1 hydroxylase (CYP7B1) attenuates metabolic-associated fatty liver disease in mice at thermoneutrality[J]","volume":"10","author":"Evangelakos","year":"2021","journal-title":"Cells"},{"issue":"12","key":"10.1016\/j.jnutbio.2025.110136_bib0026","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1194\/jlr.RA120000924","article-title":"Insulin resistance dysregulates CYP7B1 leading to oxysterol accumulation: a pathway for NAFL to NASH transition[J]","volume":"61","author":"Kakiyama","year":"2020","journal-title":"J Lipid Res"},{"issue":"4","key":"10.1016\/j.jnutbio.2025.110136_bib0027","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.apsb.2019.02.004","article-title":"Ablation of gut microbiota alleviates obesity-induced hepatic steatosis and glucose intolerance by modulating bile acid metabolism in hamsters[J]","volume":"9","author":"Sun","year":"2019","journal-title":"Acta Pharmaceutica Sinica B"},{"issue":"4","key":"10.1016\/j.jnutbio.2025.110136_bib0028","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1083\/jcb.141.4.863","article-title":"Nucleocytoplasmic shuttling factors including Ran and CRM1 mediate nuclear export of NFAT in vitro[J]","volume":"141","author":"Kehlenbach","year":"1998","journal-title":"J Cell Biol"},{"issue":"10","key":"10.1016\/j.jnutbio.2025.110136_bib0029","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s11745-014-3947-y","article-title":"Dietary hyodeoxycholic acid exerts hypolipidemic effects by reducing farnesoid X receptor antagonist bile acids in mouse enterohepatic tissues[J]","volume":"49","author":"Watanabe","year":"2014","journal-title":"Lipids"},{"issue":"5","key":"10.1016\/j.jnutbio.2025.110136_bib0030","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1210\/er.2018-00064","article-title":"Molecular actions of ppar\u03b1 in lipid metabolism and inflammation[J]","volume":"39","author":"Bougarne","year":"2018","journal-title":"Endocrine Rev"},{"issue":"3","key":"10.1016\/j.jnutbio.2025.110136_bib0031","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","article-title":"Molecular mechanism of ppar\u03b1 action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease[J]","volume":"62","author":"Pawlak","year":"2015","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.jnutbio.2025.110136_bib0032","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.jnutbio.2009.12.004","article-title":"Mechanisms underlying the cardioprotective effects of omega-3 polyunsaturated fatty acids[J]","volume":"21","author":"Adkins","year":"2010","journal-title":"J Nutr Biochem"},{"issue":"4","key":"10.1016\/j.jnutbio.2025.110136_bib0033","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.cmet.2020.11.017","article-title":"Hyocholic acid species improve glucose homeostasis through a distinct TGR5 and FXR signaling mechanism[J]","volume":"33","author":"Zheng","year":"2021","journal-title":"Cell Metab"},{"key":"10.1016\/j.jnutbio.2025.110136_bib0034","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.atherosclerosis.2019.05.004","article-title":"Effects of dietary intervention and n - 3 PUFA supplementation on markers of gut-related inflammation and their association with cardiovascular events in a high-risk population[J]","volume":"286","author":"Awoyemi","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jnutbio.2025.110136_bib0035","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.3389\/fmicb.2020.01835","article-title":"Effects of gut microbiome and short-chain fatty acids (SCFAs) on finishing weight of meat rabbits[J]","volume":"11","author":"Fang","year":"2020","journal-title":"Front Microbiol"},{"issue":"1","key":"10.1016\/j.jnutbio.2025.110136_bib0036","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/bmb\/ldaa006","article-title":"Obeticholic acid-a new therapy in PBC and NASH[J]","volume":"133","author":"Chapman","year":"2020","journal-title":"Br Med Bullet"},{"issue":"9","key":"10.1016\/j.jnutbio.2025.110136_bib0037","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1096\/fj.12-223008","article-title":"Hyodeoxycholic acid improves HDL function and inhibits atherosclerotic lesion formation in LDLR-knockout mice[J]","volume":"27","author":"Shih","year":"2013","journal-title":"Faseb J"},{"issue":"4","key":"10.1016\/j.jnutbio.2025.110136_bib0038","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/hep.28712","article-title":"Farnesoid X receptor activation increases reverse cholesterol transport by modulating bile acid composition and cholesterol absorption in mice[J]","volume":"64","author":"Xu","year":"2016","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jnutbio.2025.110136_bib0039","doi-asserted-by":"crossref","first-page":"10166","DOI":"10.1038\/ncomms10166","article-title":"Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction[J]","volume":"6","author":"Jiang","year":"2015","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.jnutbio.2025.110136_bib0040","doi-asserted-by":"crossref","DOI":"10.1128\/mSystems.00070-16","article-title":"Farnesoid X receptor signaling shapes the gut microbiota and controls hepatic lipid metabolism[J]","volume":"1","author":"Zhang","year":"2016","journal-title":"Msystems"},{"issue":"5","key":"10.1016\/j.jnutbio.2025.110136_bib0041","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.tem.2014.03.007","article-title":"Glucose-lowering effects of intestinal bile acid sequestration through enhancement of splanchnic glucose utilization[J]","volume":"25","author":"Prawitt","year":"2014","journal-title":"Trends Endocrinol Metabol"},{"issue":"30","key":"10.1016\/j.jnutbio.2025.110136_bib0042","doi-asserted-by":"crossref","first-page":"26913","DOI":"10.1074\/jbc.M111.248203","article-title":"Lowering bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes through reduced energy expenditure[J]","volume":"286","author":"Watanabe","year":"2011","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.jnutbio.2025.110136_bib0043","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1038\/ncomms3384","article-title":"Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity[J]","volume":"4","author":"Li","year":"2013","journal-title":"Nat Comms"},{"issue":"7499","key":"10.1016\/j.jnutbio.2025.110136_bib0044","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nature13135","article-title":"FXR is a molecular target for the effects of vertical sleeve gastrectomy[J]","volume":"509","author":"Ryan","year":"2014","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.jnutbio.2025.110136_bib0045","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.2337\/db11-0030","article-title":"Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity[J]","volume":"60","author":"Prawitt","year":"2011","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.jnutbio.2025.110136_bib0046","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev-physiol-031620-093815","article-title":"Ceramides in metabolism: key lipotoxic players[J]","volume":"83","author":"Chaurasia","year":"2021","journal-title":"Ann Rev Physiol"},{"issue":"5","key":"10.1016\/j.jnutbio.2025.110136_bib0047","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.cmet.2019.09.016","article-title":"Adipocyte hypoxia-inducible factor 2\u03b1 suppresses atherosclerosis by promoting adipose ceramide catabolism[J]","volume":"30","author":"Zhang","year":"2019","journal-title":"Cell Metab"},{"issue":"4","key":"10.1016\/j.jnutbio.2025.110136_bib0048","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.cmet.2014.08.002","article-title":"Obesity-induced CerS6-dependent ceramide production promotes weight gain and glucose intolerance[J]","volume":"20","author":"Turpin","year":"2014","journal-title":"Cell Metab"},{"issue":"10","key":"10.1016\/j.jnutbio.2025.110136_bib0049","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.tem.2015.07.006","article-title":"Ceramides - lipotoxic inducers of metabolic disorders[J]","volume":"26","author":"Chaurasia","year":"2015","journal-title":"Trends Endocrin Met"},{"key":"10.1016\/j.jnutbio.2025.110136_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101238","article-title":"Metabolic-associated fatty liver disease and lipoprotein metabolism[J]","volume":"50","author":"Heeren","year":"2021","journal-title":"Mol Metabol"},{"key":"10.1016\/j.jnutbio.2025.110136_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115157","article-title":"Ceramide de novo synthesis in non-alcoholic fatty liver disease: pathogenic mechanisms and therapeutic perspectives[J]","volume":"202","author":"Yu","year":"2022","journal-title":"Biochem Pharmacol"}],"container-title":["The Journal of Nutritional Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955286325002980?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955286325002980?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T11:48:49Z","timestamp":1764416929000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0955286325002980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":51,"alternative-id":["S0955286325002980"],"URL":"https:\/\/doi.org\/10.1016\/j.jnutbio.2025.110136","relation":{},"ISSN":["0955-2863"],"issn-type":[{"value":"0955-2863","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"n - 3 polyunsaturated fatty acids mediate hyodeoxycholic acid-FXR signaling to ameliorate metabolic dysfunction-associated fatty liver disease","name":"articletitle","label":"Article Title"},{"value":"The Journal of Nutritional Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jnutbio.2025.110136","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110136"}}